<DOC>
	<DOCNO>NCT02443883</DOCNO>
	<brief_summary>The main purpose study evaluate safety feasibility administer high dos ramucirumab participant gastric cancer .</brief_summary>
	<brief_title>A Phase 2 Study Ramucirumab ( LY3009806 ) Participants With Gastric Gastroesophageal Junction ( GEJ ) Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The participant histopathologically cytologically confirm diagnosis gastric gastroesophageal junction ( GEJ ) . The participant document disease progression within 4 month last dose firstline chemotherapy metastatic disease , within 6 month last dose neoadjuvant adjuvant therapy . The participant receive combination chemotherapy prior disease progression . Prior chemotherapy regimen must include platinum and/or fluoropyrimidine component must include taxane antiangiogenic agent . The participant metastatic disease locally advanced disease measurable nonmeasurable , evaluable disease radiological image per Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST 1.1 ) . The participant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . The participant adequate organ function , include : Total bilirubin 1.5 × upper limit institutional normal ( ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 3 × ULN . If liver tumor involvement , AST ALT &lt; 5 × ULN acceptable . Serum creatinine 1.5 × ULN calculate creatinine clearance ( per CockcroftGault formula equivalent and/or 24hour urine collection ) 60 milliliters/minute ( mL/min ) . Urinary protein &lt; 2+ dipstick routine urinalysis . Absolute neutrophil count 1.5 × 10^9/Liter ( L ) , platelets 100 × 10^9/L , hemoglobin 9 g/deciliter ( dL ) ( 5.58 millimoles/Liter ) . International normalize ratio 1.5 × ULN prothrombin time 5 second ULN . Partial thromboplastin time 5 second ULN . The participant estimate life expectancy 12 week judgment investigator . The participant , female childbearing potential , must negative serum urine pregnancy test within 7 day prior randomization . The participant squamous cell undifferentiated gastric cancer . The participant receive chronic therapy follow within 7 day prior randomization : Nonsteroidal antiinflammatory agent ( NSAIDs ; indomethacin , ibuprofen , naproxen , similar agent ) , Other antiplatelet agent ( clopidogrel , ticlopidine , dipyridamole , anagrelide ) . Aspirin use dose 325 milligram ( mg ) /day permit . The participant receive radiotherapy within 14 day prior randomization . The participant receive &gt; 1 line prior therapy treatment locally advance unresectable metastatic gastric GEJ ( Siewert Types IIII ) adenocarcinoma . The participant receive previous treatment agent target vascular endothelial growth factor ( VEGF ) /VEGF receptor 2 signal pathway . The participant document brain metastasis , leptomeningeal disease , uncontrolled spinal cord compression . The participant experience arterial thromboembolic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack , within 6 month prior randomization . The participant symptomatic congestive heart failure ( New York Heart Association IIIV ) symptomatic poorly control cardiac arrhythmia . The participant uncontrolled hypertension , define Common Terminology Criteria Adverse Events ( CTCAE ) Version 4.0 , prior initiate study treatment , despite antihypertensive intervention . The participant underwent major surgery within 28 day prior randomization central venous access device placement within 7 day prior randomization . The participant history gastrointestinal perforation fistula within 6 month prior randomization . The participant condition ( example , psychological , geographical , medical ) permit compliance study followup procedure suggest participant , investigator 's opinion , appropriate candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stomach cancer</keyword>
</DOC>